Nivolumab

Bristol-Myers Squibb (BMS), the maker of the immunotherapy drug Odpivo® (nivolumab), announced yesterday that a phase III trial of the drug in patients with advanced non-small cell lung cancer (NSCLC) was being stopped…

Today the FDA announced the approval of the immunotherapy Opdivo® (nivolumab) for the treatment of advanced squamous non-small cell lung cancer (NSCLC), making it the first immunotherapy approved for that indication.…

Today, a phase III trial of the immunotherapy drug nivolumab (Opdivo®) in patients with advanced kidney cancer was stopped early because results showed a clear benefit to patients: those receiving nivolumab lived longer…

In March of this year, the immunotherapy drug nivolumab (Opdivo®), made by Bristol-Myers Squibb, became the first immunotherapy approved by the FDA for the treatment of lung cancer that has stopped responding to…

New hope now exists for patients with advanced kidney cancer. Yesterday, the FDA approved the immunotherapy drug nivolumab (Opdivo®, Bristol-Myers Squibb) to treat metastatic renal cell carcinoma (RCC)—the most common…

Today, the FDA approved the use of nivolumab (Opdivo)―an anti-PD-1 antibody―to treat classical Hodgkin lymphoma. This is the first checkpoint immunotherapy approved for any type of lymphoma, and CRI is happy to know of…

On Friday, August 17, the FDA approved the first immunotherapy—the checkpoint inhibitor nivolumab (Opdivo®, Bristol-Myers Squibb)—for patients with small cell lung cancer (SCLC).  This approval, which was based on the…